There are currently no standard treatments that slow or stop Parkinson’s disease — available therapies address each patient’s individual symptoms. Now, a breakthrough study successfully identifies two existing antimalaria drugs that show promise in targeting disease progress.

The international team behind the study — including members from Nanyang Technological University (NTU) in Singapore and McLean Hospital and Harvard Medical School in Belmont, MA — reports the findings in the Proceedings of the National Academy of Sciences.

An estimated 10 million people worldwide are living with Parkinson’s disease — a progressive, neurological disorder that mostly strikes after middle age.


Continue Reading

This article originally appeared on Psychiatry Advisor

READ FULL ARTICLE Curated publisher From Medical News Today